Data Showcase Compound’s Discovery through Development and
Potential to Expand Echinocandin Utility Across Multiple
Infectious-Disease Indications
SAN DIEGO –
Cidara Therapeutics, Inc. (Nasdaq:CDTX), a biotechnology company
developing novel anti-infectives including immunotherapies, today
announced that data from preclinical and clinical studies evaluating the
company’s novel echinocandin antifungal CD101 appear in the December 5
online issue of the journal Antimicrobial Agents and Chemotherapy
(AAC). These latest findings add to the growing body of published
scientific evidence that demonstrate the unique attributes of Cidara’s
lead antifungal drug candidate and showcase the compound’s strategic
discovery and rapid development.
“The publication of these latest findings in AAC further affirms
the clinical utility, safety and unique profile of CD101 across a number
of infectious-disease indications, including treatment and prophylaxis
of invasive fungal infections and treatment of vulvovaginal
candidiasis,” said Jeffrey Stein, Ph.D., president and chief executive
officer of Cidara. “We now have a compendium of published data on CD101
that demonstrate the quality and scientific rigor behind our antifungal
drug development program. The discovery and development of CD101 has
unlocked a molecule, now in multiple Phase 2 clinical trials, with
differentiating properties and utility far beyond that of currently
approved echinocandins.”
In total, seven CD101 manuscripts were published during the second half
of 2016:
-
Safety and Pharmacokinetics of CD101 IV, a Novel Echinocandin, in
Healthy Adults, Antimicrobial Agents and Chemotherapy, December
2016 -
Structure-Activity Relationships of a Series of Echinocandins and the
Discovery of CD101, a Highly Stable and Soluble Echinocandin with
Distinctive Pharmacokinetic Properties, Antimicrobial Agents and
Chemotherapy, December 2016 -
Preclinical Evaluation of the Stability, Safety and Efficacy of CD101,
a Novel Echinocandin, Antimicrobial Agents and Chemotherapy,
November 2016, Volume 60, Issue 11 -
Activity of a long-acting echinocandin, CD101, determined using CLSI
and EUCAST reference methods, against Candida and Aspergillus spp.,
including echinocandin- and azole-resistant isolates, Journal of
Antimicrobial and Chemotherapy, October 2016, Volume 71, Issue 10 -
Characterization of in vitro resistance development to the novel
echinocandin, CD101, in Candida species, Antimicrobial Agents and
Chemotherapy, September 2016, Volume 60, Issue 10 -
CD101: a novel long-acting echinocandin, Cell Microbiology,
September 2016, Volume 18, Issue 9 -
CD101, a novel echinocandin with exceptional stability properties and
enhanced aqueous solubility, The Journal of Antibiotics, August
2016
Links to the full text of these publications are also available on the
Cidara website: https://www.cidara.com/publications/
About Invasive Fungal Infections
Fungal infections can carry a mortality rate of 35-50 percent, higher
than most bacterial infections. Approximately 97,000 Americans die from
hospital-related fungal infections each year and 90 percent of these
infections are caused by two common fungi, Candida and Aspergillus.
There is an urgent and growing need for new therapeutic approaches to
treat and prevent serious invasive fungal infections.
About Vulvovaginal Candidiasis (VVC)
Vulvovaginal candidiasis (VVC) is a highly prevalent mucosal fungal
infection which impacts approximately 75 percent of women in America.
Many have moderate to severe symptoms and four to five million are
estimated to have recurrent infections. Current VVC treatments have
significant limitations and there have been no novel therapies approved
for the condition in more than 20 years. Between 30 to 40 percent of
women fail acute VVC therapy and 50 percent relapse with recurrent VVC
within six months. Current therapies are fungistatic, not fungicidal
(meaning they inhibit the growth of fungus but may not kill the fungus),
and do not cover non-albicans Candida strains.
About Cidara Therapeutics
Cidara is a clinical-stage biotechnology company focused on developing
new anti-infectives that have the potential to transform the standard of
care and save or improve patients’ lives. The company is currently
advancing its novel echinocandin antifungal, CD101, through Phase 2
studies in two indications and developing CD201, its bispecific
antimicrobial immunotherapy, for the treatment of multi-drug resistant
bacterial infections. CD101 IV has enhanced potency and is the only
once-weekly therapy intended for the treatment and prevention of
life-threatening invasive fungal infections. CD101 topical is the first
and only agent of its class being studied for the treatment and
prevention of vulvovaginal candidiasis (VVC), a prevalent mucosal
infection. CD201 is the first drug candidate selected from Cidara’s
novel Cloudbreak™ platform, the first immunotherapy discovery platform
designed specifically to create compounds that direct a patient’s immune
cells to attack and eliminate bacterial, fungal or viral pathogens.
Cidara is headquartered in San Diego, California. For more information,
please visit www.cidara.com.
Forward-Looking Statements
Statements contained in this press release regarding matters that are
not historical facts are “forward-looking statements” within the meaning
of the Private Securities Litigation Reform Act of 1995. Because such
statements are subject to risks and uncertainties, actual results may
differ materially from those expressed or implied by such
forward-looking statements. Such statements include, but are not limited
to, statements regarding the effectiveness, safety, long-acting nature,
anticipated human dosing and other attributes of CD101, and its
differentiation from other therapies. Risks that contribute to the
uncertain nature of the forward-looking statements include: the success
and timing of Cidara’s preclinical studies and clinical trials;
regulatory developments in the United States and foreign countries;
changes in Cidara’s plans to develop and commercialize its product
candidates; Cidara’s ability to obtain additional financing; Cidara’s
ability to obtain and maintain intellectual property protection for its
product candidates; and the loss of key scientific or management
personnel. These and other risks and uncertainties are described more
fully in Cidara’s Form 10-Q most recently filed with the United States
Securities and Exchange Commission. All forward-looking statements
contained in this press release speak only as of the date on which they
were made. Cidara undertakes no obligation to update such statements to
reflect events that occur or circumstances that exist after the date on
which they were made.
View source version on businesswire.com: http://www.businesswire.com/news/home/20161214005351/en/
INVESTORS:
Westwicke Partners, LLC
Robert H. Uhl,
858-356-5932
Managing Director
robert.uhl@westwicke.com
or
MEDIA:
Sam
Brown Inc.
Christy Curran, 615-414-8668
ChristyCurran@sambrown.com
